{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "http://eldaddp.azurewebsites.net/answeredquestions.text?min-answer.questionFirstAnswered.=2019-01-07T16%3A18%3A47.217Z&hansardHeading=Drugs", "definition" : "http://eldaddp.azurewebsites.net/meta/answeredquestions.text?min-answer.questionFirstAnswered.=2019-01-07T16%3A18%3A47.217Z&hansardHeading=Drugs", "extendedMetadataVersion" : "http://eldaddp.azurewebsites.net/answeredquestions.text?min-answer.questionFirstAnswered.=2019-01-07T16%3A18%3A47.217Z&_metadata=all&hansardHeading=Drugs", "first" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=0&min-answer.questionFirstAnswered.=2019-01-07T16%3A18%3A47.217Z&hansardHeading=Drugs", "hasPart" : "http://eldaddp.azurewebsites.net/answeredquestions.text?min-answer.questionFirstAnswered.=2019-01-07T16%3A18%3A47.217Z&hansardHeading=Drugs", "isPartOf" : "http://eldaddp.azurewebsites.net/answeredquestions.text?min-answer.questionFirstAnswered.=2019-01-07T16%3A18%3A47.217Z&hansardHeading=Drugs", "items" : [{"_about" : "http://data.parliament.uk/resources/1693948", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1693948/answer", "answerText" : {"_value" : "<p>There are around 14,000 licensed medicines, and the overwhelming majority are in good supply. However, the medicine supply chain is highly regulated, complex, and global and supply disruption is an issue which affects countries all around the world.<\/p><p>The Department\u2019s medicines Discontinuations and Shortages (DaSH) portal was established in October 2020 to collect notifications from suppliers of potential supply issues. Data from before October 2020 cannot be provided as this information is not held. The following table shows the number of supply issue notifications added to the DaSH portal, each month since 2020:<\/p><table><tbody><tr><td><p>Month added to DaSH<\/p><\/td><td><p>Number of supply issue notifications<\/p><\/td><\/tr><tr><td><p>October 2020<\/p><\/td><td><p>180<\/p><\/td><\/tr><tr><td><p>November 2020<\/p><\/td><td><p>130<\/p><\/td><\/tr><tr><td><p>December 2020<\/p><\/td><td><p>90<\/p><\/td><\/tr><tr><td><p>January 2021<\/p><\/td><td><p>90<\/p><\/td><\/tr><tr><td><p>February 2021<\/p><\/td><td><p>70<\/p><\/td><\/tr><tr><td><p>March 2021<\/p><\/td><td><p>60<\/p><\/td><\/tr><tr><td><p>April 2021<\/p><\/td><td><p>50<\/p><\/td><\/tr><tr><td><p>May 2021<\/p><\/td><td><p>60<\/p><\/td><\/tr><tr><td><p>June 2021<\/p><\/td><td><p>130<\/p><\/td><\/tr><tr><td><p>July 2021<\/p><\/td><td><p>60<\/p><\/td><\/tr><tr><td><p>August 2021<\/p><\/td><td><p>100<\/p><\/td><\/tr><tr><td><p>September 2021<\/p><\/td><td><p>90<\/p><\/td><\/tr><tr><td><p>October 2021<\/p><\/td><td><p>80<\/p><\/td><\/tr><tr><td><p>November 2021<\/p><\/td><td><p>100<\/p><\/td><\/tr><tr><td><p>December 2021<\/p><\/td><td><p>100<\/p><\/td><\/tr><tr><td><p>January 2022<\/p><\/td><td><p>110<\/p><\/td><\/tr><tr><td><p>February 2022<\/p><\/td><td><p>130<\/p><\/td><\/tr><tr><td><p>March 2022<\/p><\/td><td><p>70<\/p><\/td><\/tr><tr><td><p>April 2022<\/p><\/td><td><p>100<\/p><\/td><\/tr><tr><td><p>May 2022<\/p><\/td><td><p>120<\/p><\/td><\/tr><tr><td><p>June 2022<\/p><\/td><td><p>140<\/p><\/td><\/tr><tr><td><p>July 2022<\/p><\/td><td><p>210<\/p><\/td><\/tr><tr><td><p>August 2022<\/p><\/td><td><p>140<\/p><\/td><\/tr><tr><td><p>September 2022<\/p><\/td><td><p>180<\/p><\/td><\/tr><tr><td><p>October 2022<\/p><\/td><td><p>130<\/p><\/td><\/tr><tr><td><p>November 2022<\/p><\/td><td><p>180<\/p><\/td><\/tr><tr><td><p>December 2022<\/p><\/td><td><p>110<\/p><\/td><\/tr><tr><td><p>January 2023<\/p><\/td><td><p>170<\/p><\/td><\/tr><tr><td><p>February 2023<\/p><\/td><td><p>130<\/p><\/td><\/tr><tr><td><p>March 2023<\/p><\/td><td><p>140<\/p><\/td><\/tr><tr><td><p>April 2023<\/p><\/td><td><p>120<\/p><\/td><\/tr><tr><td><p>May 2023<\/p><\/td><td><p>120<\/p><\/td><\/tr><tr><td><p>June 2023<\/p><\/td><td><p>130<\/p><\/td><\/tr><tr><td><p>July 2023<\/p><\/td><td><p>130<\/p><\/td><\/tr><tr><td><p>August 2023<\/p><\/td><td><p>160<\/p><\/td><\/tr><tr><td><p>September 2023<\/p><\/td><td><p>110<\/p><\/td><\/tr><tr><td><p>October 2023<\/p><\/td><td><p>130<\/p><\/td><\/tr><tr><td><p>November 2023<\/p><\/td><td><p>170<\/p><\/td><\/tr><tr><td><p>December 2023<\/p><\/td><td><p>140<\/p><\/td><\/tr><tr><td><p>January 2024<\/p><\/td><td><p>160<\/p><\/td><\/tr><\/tbody><\/table>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4044", "label" : {"_value" : "Biography information for Andrew Stephenson"}
        }
        , "answeringMemberConstituency" : {"_value" : "Pendle"}
        , "answeringMemberPrinted" : {"_value" : "Andrew Stephenson"}
        , "dateOfAnswer" : {"_value" : "2024-03-21", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/1693948/answer/previousversion/22710", "answeringMember" : {"_about" : "http://data.parliament.uk/members/4044", "label" : {"_value" : "Biography information for Andrew Stephenson"}
          }
          , "answeringMemberConstituency" : {"_value" : "Pendle"}
          , "answeringMemberPrinted" : {"_value" : "Andrew Stephenson"}
        }
        , "questionFirstAnswered" : [{"_value" : "2024-03-21T13:57:11.977Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2024-03-05", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Drugs"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, how many medicine supply issue notifications her Department has received in each month since 2017.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4603", "label" : {"_value" : "Biography information for Preet Kaur Gill"}
      }
      , "tablingMemberConstituency" : {"_value" : "Birmingham, Edgbaston"}
      , "tablingMemberPrinted" : [{"_value" : "Preet Kaur Gill"}
      ], "uin" : "17245"}
    , {"_about" : "http://data.parliament.uk/resources/1685919", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1685919/answer", "answerText" : {"_value" : "<p>The Department has well-established tools and processes to manage supply issues whenever they arise, helping to prevent shortages and mitigate risks to patients. We work with industry, NHS England, the Medicines and Healthcare products Regulatory Agency, devolved administrations and other stakeholders to help ensure patients continue to have access to the treatments they need.<\/p><p>The Department has been working with industry to help boost supplies of medicines for the treatment of type 2 diabetes, and the position is improving as a result. Some supply issues remain, but we are continuing to work hard to resolve these as quickly as possible. We have issued guidance to all healthcare professionals on how to manage patients requiring these medicines whilst supply is disrupted. Our guidance is clear that medicines licensed for the treatment of type 2 diabetes should only be used for this purpose.<\/p><p>Regarding cancer medicines, we are aware of an issue with the supply of letrozole tablets from one supplier. We have been working with alternative suppliers, who have confirmed that they have the stock available to meet demand. A supplier of tamoxifen tablets is also experiencing supply issues, but again we have worked with alternative suppliers to help ensure they can support the market at this time.<\/p><p>Regarding medicines for mental health treatments, the Department has been working with manufacturers of attention deficit hyperactivity disorder medicines and a number of issues have now been resolved. Work continues to resolve the remaining supply issues by April 2024. We have issued a National Patient Safety Alert and worked with clinicians to develop helpful guidance on how to manage patients during this time.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4044", "label" : {"_value" : "Biography information for Andrew Stephenson"}
        }
        , "answeringMemberConstituency" : {"_value" : "Pendle"}
        , "answeringMemberPrinted" : {"_value" : "Andrew Stephenson"}
        , "dateOfAnswer" : {"_value" : "2024-02-05", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2024-02-05T15:34:52.95Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2024-01-30", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Drugs"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what steps her Department is taking to secure supplies of medicines for (a) diabetes, (b) cancer and (c) mental health treatments.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4738", "label" : {"_value" : "Biography information for Alyn Smith"}
      }
      , "tablingMemberConstituency" : {"_value" : "Stirling"}
      , "tablingMemberPrinted" : [{"_value" : "Alyn Smith"}
      ], "uin" : "12108"}
    , {"_about" : "http://data.parliament.uk/resources/1452003", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1452003/answer", "answerText" : {"_value" : "<p>The Medicines and Healthcare products Regulatory Agency (MHRA) is an independent regulator working on a nominal fee for licence applications and regulating the industry. The MHRA is funded predominantly by income from fees for both statutory and non-statutory sales of products and services, which includes working with pharmaceutical companies.<\/p><p>As civil servants, all staff are committed to the core values of integrity, honesty, objectivity and impartiality. Additionally, staff are not permitted to have any personal financial connections to pharmaceutical companies or medical device manufacturers.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4909", "label" : {"_value" : "Biography information for Lord Kamall"}
        }
        , "answeringMemberPrinted" : {"_value" : "Lord Kamall"}
        , "dateOfAnswer" : {"_value" : "2022-03-24", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2022-03-24T15:52:54.737Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2022-03-16", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Drugs"}
      , "houseId" : {"_value" : "2"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"}
      }
      ], "questionText" : "To ask Her Majesty's Government what links there are (1) legally, (2) administratively, and (3) financially, between the Medicines and Healthcare products Regulatory Agency and pharmaceutical companies.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/134", "label" : {"_value" : "Biography information for Lord Framlingham"}
      }
      , "tablingMemberPrinted" : [{"_value" : "Lord Framlingham"}
      ], "uin" : "HL7016"}
    , {"_about" : "http://data.parliament.uk/resources/1277359", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1277359/answer", "answerText" : {"_value" : "<p>The noble Lord Carter of Coles published a report last year on the provision of aseptic medicines, including some critical care medicines, in England. Recommendations included setting up a network of hub and spoke facilities to prepare ready to administer medicines, providing guidance on standard injectable medicines, and training for aseptic pharmacy staff. NHS England and NHS Improvement are setting up a National Health Service aseptic services transformation implementation board to co-ordinate the implementation of these recommendations.<\/p><p>The recommended changes will improve patient safety by reducing errors in compounding and administering these medicines. Errors in these medicines are not currently specifically tracked but the report recommends that the NHS begins tracking and reducing them.<\/p><p>The creation of regional hub and spoke services could release the equivalent of over 4,000 whole time equivalent nurses each year. This is based on the time taken for nurses to prepare the 14 most commonly used aseptic medicines. The development of a hub and spoke system will offer opportunities for production at scale, relieving pressure on hospital pharmacies.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4708", "label" : {"_value" : "Biography information for Lord Bethell"}
        }
        , "answeringMemberPrinted" : {"_value" : "Lord Bethell"}
        , "dateOfAnswer" : {"_value" : "2021-02-01", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2021-02-01T12:39:37.187Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2021-01-18", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Drugs"}
      , "houseId" : {"_value" : "2"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"}
      }
      ], "questionText" : "To ask Her Majesty's Government what steps they are taking to support and advise NHS Trusts on \u2018ready to use\u2019 medicines which (1) improve patient safety through reduced drug administration errors, (2) save nursing time, and (3) relieve pressure on pharmacy teams.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1850", "label" : {"_value" : "Biography information for Baroness Masham of Ilton"}
      }
      , "tablingMemberPrinted" : [{"_value" : "Baroness Masham of Ilton"}
      ], "uin" : "HL12227"}
    , {"_about" : "http://data.parliament.uk/resources/1243075", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1243075/answer", "answerText" : {"_value" : "<p>As part of our concerted national efforts to respond to the COVID-19 outbreak, we are doing everything we can to ensure patients continue to have access to COVID-19 medicines in all scenarios. This includes holding stockpiles of a variety of medicines currently and potentially used in treating patients with COVID-19, to help ensure there is uninterrupted supply over the coming months.<\/p><p>As set out in a letter from the Department to industry of 3 August, we are implementing a multi-layered approach to the end of the Transition Period, that involves asking suppliers of medicines and medical products to the United Kingdom from or via the European Union to get trader ready, reroute their supply chains away from any potential disruption and stockpiling to a target level of six weeks on UK soil where this is possible. The letter is available at the following link:<\/p><p><a href=\"https://www.gov.uk/government/publications/letter-to-medicines-and-medical-products-suppliers-3-august-2020/letter-to-medicine-suppliers-3-august-2020\" target=\"_blank\">https://www.gov.uk/government/publications/letter-to-medicines-and-medical-products-suppliers-3-august-2020/letter-to-medicine-suppliers-3-august-2020<\/a><\/p><p>Any information on suppliers\u2019 stock levels that has been shared with the Department to support contingency planning is commercially sensitive and cannot be shared with third parties.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4380", "label" : {"_value" : "Biography information for Jo Churchill"}
        }
        , "answeringMemberConstituency" : {"_value" : "Bury St Edmunds"}
        , "answeringMemberPrinted" : {"_value" : "Jo Churchill"}
        , "dateOfAnswer" : {"_value" : "2020-10-22", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2020-10-22T09:41:33.353Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2020-10-13", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Drugs"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what recent assessment he has made of the extent of stockpiling of medicines in preparation for (a) a second wave of covid-19 and (b) the end of the transition period, and if he will publish that assessment.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1533", "label" : {"_value" : "Biography information for Dame Diana Johnson"}
      }
      , "tablingMemberConstituency" : {"_value" : "Kingston upon Hull North"}
      , "tablingMemberPrinted" : [{"_value" : "Dame Diana Johnson"}
      ], "uin" : "102708"}
    , {"_about" : "http://data.parliament.uk/resources/1231229", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1231229/answer", "answerText" : {"_value" : "<p>The Department, in consultation with the devolved administrations and Crown Dependencies, is working with trade bodies, product suppliers, and the health and care system in England to make detailed plans to help ensure continued supply of medicines and medical products, including medical radioisotopes and over-the-counter medicines, to the whole of the United Kingdom at the end of the transition period in all scenarios.<\/p><p>The Department understands that a flexible approach to preparedness may be required for medicines that cannot be stockpiled, such as some medical radioisotopes. We have asked suppliers of those products to use airfreight, which some suppliers are already doing now.<\/p><p> <\/p><p>Further detail on the plans to help ensure continuity of medical supplies has been communicated to suppliers, and can be found at the following link:<\/p><p><a href=\"https://www.gov.uk/government/publications/letter-to-medicines-and-medical-products-suppliers-3-august-2020/letter-to-medicine-suppliers-3-august-2020\" target=\"_blank\">https://www.gov.uk/government/publications/letter-to-medicines-and-medical-products-suppliers-3-august-2020/letter-to-medicine-suppliers-3-august-2020<\/a><\/p><p> <\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4362", "label" : {"_value" : "Biography information for Edward Argar"}
        }
        , "answeringMemberConstituency" : {"_value" : "Charnwood"}
        , "answeringMemberPrinted" : {"_value" : "Edward Argar"}
        , "dateOfAnswer" : {"_value" : "2020-09-10", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : {"_value" : "84731"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/1231229/answer/previousversion/45730", "answeringMember" : {"_about" : "http://data.parliament.uk/members/4380", "label" : {"_value" : "Biography information for Jo Churchill"}
          }
          , "answeringMemberConstituency" : {"_value" : "Bury St Edmunds"}
          , "answeringMemberPrinted" : {"_value" : "Jo Churchill"}
        }
        , "questionFirstAnswered" : [{"_value" : "2020-09-10T18:16:23.477Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2020-09-03", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Drugs"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what steps his Department is taking to ensure that the public have uninterrupted access to over the counter medicines in the event of the UK leaving the EU without a deal.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4656", "label" : {"_value" : "Biography information for Layla Moran"}
      }
      , "tablingMemberConstituency" : {"_value" : "Oxford West and Abingdon"}
      , "tablingMemberPrinted" : [{"_value" : "Layla Moran"}
      ], "uin" : "84734"}
    , {"_about" : "http://data.parliament.uk/resources/1203560", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1203560/answer", "answerText" : {"_value" : "<p>The United Kingdom left the European Union on 31 January and is now in a Transition Period until 31 December 2020. During this time, it remains our objective to negotiate a future relationship with the EU and in our respective published negotiating documents, we have both stated objectives to reach an agreement on trade in goods. The UK\u2019s published approach sets out how we want to facilitate trade in medicinal products and support high levels of patient safety.<\/p><p>The Government, pharmaceutical industry and National Health Service will always work closely together to help ensure patients continue to have access, to the medicines and treatments they need, including insulin, under all scenarios.<\/p><p>The Department has well-established procedures to deal with medicine shortages and is working closely with industry, the NHS and others in the supply chain to reduce the likelihood of future shortages resulting from any cause.<\/p><p> <\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4708", "label" : {"_value" : "Biography information for Lord Bethell"}
        }
        , "answeringMemberPrinted" : {"_value" : "Lord Bethell"}
        , "dateOfAnswer" : {"_value" : "2020-06-30", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : {"_value" : "HL5713"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2020-06-30T15:47:39.5Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2020-06-15", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Drugs"}
      , "houseId" : {"_value" : "2"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"}
      }
      ], "questionText" : "Her Majesty's Government what assessment they have made about whether any drugs or medicines will be in short supply after the UK leaves the EU.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/3691", "label" : {"_value" : "Biography information for Lord Roberts of Llandudno"}
      }
      , "tablingMemberPrinted" : [{"_value" : "Lord Roberts of Llandudno"}
      ], "uin" : "HL5715"}
    , {"_about" : "http://data.parliament.uk/resources/1186624", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1186624/answer", "answerText" : {"_value" : "<p>The Government has no plans to create facilities in the United Kingdom to manufacture further active pharmaceutical ingredients. There are 16,000 medicines on the market in the UK. Whilst some of these are manufactured in the UK, most are manufactured abroad. Where medicines are manufactured here, the active ingredients and excipients for those medicines may be manufactured abroad. It is not realistic to manufacture all 16,000 medicines and the active ingredients and excipients needed for these medicines in the UK.<\/p><p>The production of medicines is complex and highly regulated, and materials and processes must meet rigorous safety and quality standards. Supply problems can affect a wide range of medicines and can arise for various reasons, such as manufacturing issues, problems with the raw ingredients and batch failures. These problems arise regardless of where in the world the manufacture takes place.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4380", "label" : {"_value" : "Biography information for Jo Churchill"}
        }
        , "answeringMemberConstituency" : {"_value" : "Bury St Edmunds"}
        , "answeringMemberPrinted" : {"_value" : "Jo Churchill"}
        , "dateOfAnswer" : {"_value" : "2020-04-14", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/1186624/answer/previousversion/14443", "answeringMember" : {"_about" : "http://data.parliament.uk/members/4380", "label" : {"_value" : "Biography information for Jo Churchill"}
          }
          , "answeringMemberConstituency" : {"_value" : "Bury St Edmunds"}
          , "answeringMemberPrinted" : {"_value" : "Jo Churchill"}
        }
        , "questionFirstAnswered" : [{"_value" : "2020-04-14T14:50:24.04Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2020-03-19", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Drugs"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what plans he has to manufacture more active pharmaceutical ingredients in the UK to prevent medicine shortages.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4779", "label" : {"_value" : "Biography information for Taiwo Owatemi"}
      }
      , "tablingMemberConstituency" : {"_value" : "Coventry North West"}
      , "tablingMemberPrinted" : [{"_value" : "Taiwo Owatemi"}
      ], "uin" : "32261"}
    ], "itemsPerPage" : 10, "page" : 0, "startIndex" : 1, "totalResults" : 8, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]}
}